Last reviewed · How we verify

NCT05685186

A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults

Active, enrolled Last updated 29 April 2025
What this trial tests

trial testing Spirometry in Primary Ciliary Dyskinesia in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 March 2023
Primary endpoint
28 April 2025
30 June 2025

Quick facts

Lead sponsorReCode Therapeutics
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment50
Start date8 March 2023
Primary completion28 April 2025
Estimated completion30 June 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

ReCode Therapeutics — full company profile →

Who can join

Adults 18 to 60, any sex, with Primary Ciliary Dyskinesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values. Lung function, mucociliary clearance, radiological findings, and clinical findings will be assessed. Furthermore, quality of life will be assessed using QOL-PCD, a disease specific questionnaire.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery <i>in vivo</i>.
    Zhang T, Yin H, Li Y, Yang H, et al · · 2024 · cited 42× · PMID 38770138 · DOI 10.1016/j.isci.2024.109804

Verify or expand the search:

Other trials of Spirometry

Trials testing the same drug.

Other recruiting trials for Primary Ciliary Dyskinesia

Currently open trials in the same condition.

Other ReCode Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05685186.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing